News >

FDA Halts Enrollment on 3 Nivolumab Myeloma Trials

Jason Harris
Published: Thursday, Sep 07, 2017

multiple myeloma
The FDA has placed partial clinical holds on 3 trials assessing nivolumab (Opdivo)-based combinations in patients with relapsed/refractory multiple myeloma.

Paris-based biopharmaceutical company Cellectis is developing UCART123 as a treatment for BPDCN and AML. The company said in a press release that it is working with the FDA to resume the trials with an amended protocol, including a reduced dose of UCART123 cells.
1. FDA Alerts Healthcare Professionals and Oncology Clinical Investigators about Two Clinical Trials on Hold Evaluating KEYTRUDA® (pembrolizumab) in Patients with Multiple Myeloma. Accessed August 31, 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication